Oramed Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oramed Pharmaceuticals Inc. on February 28, 2022. The report addresses a corporate governance change regarding the Company's fiscal year structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a fiscal year change and does not contain financial performance data.
Material Changes
- Fiscal Year Change: The Board of Directors approved a change to the Company's fiscal year from a period beginning September 1 and ending August 31 to a calendar year beginning January 1 and ending December 31.
- Transition Period: The change results in an abbreviated fiscal year running from September 1, 2021, to December 31, 2021.
- Future Reporting: The Company's first full calendar fiscal year under the new structure will be the year ended December 31, 2022.
Guidance, Outlook, and Risks
The Company plans to file a Transition Report on Form 10-QT to cover the transition period from September 1, 2021, to December 31, 2021. No specific guidance, management commentary on operations, or new risk factors were disclosed in this filing.
Key Facts for Investors to Verify
- Confirmation of the new fiscal year end date (December 31) for future reporting cycles.
- The upcoming filing of the Form 10-QT for the transition period (September 1, 2021 – December 31, 2021).
- Impact of the fiscal year change on the timing of future quarterly and annual earnings releases.